NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 9 – Medication<br />
Care must be taken in instilling topical ophthalmic medications to children. This is due to higher<br />
absorption, greater circulating concentrations (due to reduced blood volumes), and immature<br />
metabolic pathways increasing the half-life for elimination. Moreover medications are generally only<br />
available in adult dosages. To limit potential adverse effects, it is important to adhere to dosage<br />
times, use nasolacrimal system occlusion (if at all possible in small children) and use the minimum<br />
dose or limit the number of medications required.<br />
Treatment of children with glaucoma requires specialist consultation. While medications used in<br />
the treatment of glaucoma may not be licensed for use in children, many of them can be used<br />
safely. Topical medication is generally well tolerated however there are some notable exceptions.<br />
Table 9.7 provides an overview of the different medication options and special notes for their use<br />
in children. In particular, the central nervous system depressant effects of alpha2-agonists should<br />
not be underestimated.<br />
It is essential that all contraindications, precautions and interactions are taken into consideration<br />
when prescribing anti-glaucoma medications for children, just as for adults. When choosing a<br />
medication, the lowest possible concentration should be used in conjunction with techniques to<br />
reduce systemic absorption to minimse the potential for side effects (see Table 9.8).<br />
Evidence supports the use of topical beta-blockers, carbonic anhydrase inhibitors and prostaglandin<br />
analogues for the treatment of children with glaucoma, but with caution. Alpha2-agonists should<br />
be limited to children older than seven years of age. The alpha2-agonists have more and potentially<br />
serious adverse effects for children and are contraindicated for children younger than two years of age.<br />
Systemic use of carbonic anhydrase inhibitors is usually the last choice of management in situations<br />
where glaucoma is not satisfactorily controlled with other topical medications. They may also be<br />
considered when attempting to avoid/delay surgical intervention and prevent further glaucomatous<br />
optic neuropathy.<br />
130 National Health and Medical Research Council